Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Gilead Sciences, Inc shares valued at $617,500 were sold by Bluestone Jeffrey on Jan 20 ’26. At $123.50 per share, Bluestone Jeffrey sold 5,000 shares. The insider’s holdings dropped to 8,920 shares worth approximately $1.15 million following the completion of this transaction.
Also, JEFFREY BLUESTONE purchased 5,000 shares, netting a total of over 617,500 in proceeds.
Before that, Dickinson Andrew D had sold 3,000 shares from its account. In a trade valued at $372,930, the Chief Financial Officer traded Gilead Sciences, Inc shares for $124.31 each. Upon closing the transaction, the insider’s holdings decreased to 3,000 shares, worth approximately $19.43 million.
As of November 13, 2025, Scotiabank has initiated its “Sector outperform” rating for GILD. Earlier on August 19, 2025, Daiwa Securities upgraded its rating. Their new recommendation was “an Outperform” for GILD stock which previously was a “a Neutral”.
Analyzing GILD Stock Performance
On last trading session, Gilead Sciences, Inc [NASDAQ: GILD] rose 4.00% to $129.11. The stock’s lowest price that day was $122.68, but it reached a high of $129.39 in the same session. During the last five days, there has been a surge of approximately 6.04%. Over the course of the year, Gilead Sciences, Inc shares have jumped approximately 40.58%.
Is Gilead Sciences, Inc subject to short interest?
Stocks of Gilead Sciences, Inc saw a sharp rise in short interest on 2025-12-31 jumping by 4.67 million shares to 23.15 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 18.48 million shares. A jump of 20.19% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.51 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.51.
Which companies own the most shares of Gilead Sciences, Inc (GILD)?
In terms of Gilead Sciences, Inc share price expectations, FactSet research, analysts set an average price target of 135 in the next 12 months, up nearly 8.75% from the previous closing price of $124.14. Analysts anticipate Gilead Sciences, Inc stock to reach 150 by 2026, with the lowest price target being 105. In spite of this, 17 analysts ranked Gilead Sciences, Inc stock as Buy at the end of 2026. On August 08, 2025, Truist assigned a price target of “a Buy” to the stock and upgraded coverage with a $127.
